Kenya is set to introduce a new HIV prevention injection, Lenacapavir, which will cost Sh6,000 per dose and provide six months of protection. The groundbreaking injectable, expected to be available from January 2026, marks a major step forward in HIV prevention efforts across the country, especially for individuals struggling with adherence to daily oral PrEP medication.
Lenacapavir offers a long-acting solution by requiring only two injections per year, making it a practical and discreet alternative for many, particularly those at high risk of HIV infection. It does not, however, offer protection against other sexually transmitted infections (STIs), and should therefore be used in conjunction with other preventive methods such as condoms.
The injection has been described as a breakthrough in HIV prevention and has received global support following its approval by the U.S. Food and Drug Administration in June. The World Health Organization has recommended it as an essential addition to the array of HIV prevention tools, highlighting its potential to reduce new infections significantly, especially in sub-Saharan Africa.
Kenya is one of nine African countries selected to offer Lenacapavir through globally funded health programs. These include Nigeria, South Africa, Uganda, Zimbabwe, Zambia, Lesotho, Mozambique, and Eswatini. The selection is based on the high HIV burden and the need to introduce innovative solutions to reduce new cases.
Kenya ranks seventh globally in terms of HIV burden, with an estimated 1.4 million people living with the virus. The country’s inclusion in the early rollout reflects both the severity of the epidemic and its readiness to adopt new, science-backed interventions.
The injectable is expected to be particularly impactful among adolescent girls and young women, who face disproportionate risk due to structural, social, and economic vulnerabilities.
Global partners such as the Global Fund, UNAIDS, and Tiko Africa aim to supply at least 2 million doses, with a focus on improving access, affordability, and adherence. By expanding the prevention options available, Lenacapavir is poised to change the landscape of HIV prevention in Kenya and across the continent.
